Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05500157
Other study ID # 2020-7134
Secondary ID
Status Recruiting
Phase N/A
First received
Last updated
Start date October 1, 2022
Est. completion date October 1, 2024

Study information

Verified date May 2022
Source Radboud University Medical Center
Contact Joost P.H. Drenth
Phone +31 24 3619190
Email joostphdrenth@cs.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Patients with large hepatic cysts (> 5cm) may develop symptoms. These can be captured with the polycystic liver disease questionnaire (PLD-Q). Treatment of large hepatic cysts consists of aspiration sclerotherapy or laparoscopic fenestration. The safety and efficacy of both procedures has been explored in two recent systematic reviews yet no evident conclusion regarding superiority of either procedure could be drawn. The main objective of the ATLAS trial is to compare laparoscopic fenestration and aspiration sclerotherapy in patients with large symptomatic hepatic cysts on patient-reported outcomes.


Description:

Rationale: Patients with large hepatic cysts(>5cm) may develop symptoms due to distention of Glisson's capsule and/or compression on other abdominal organs. Frequently reported symptoms include abdominal pain, early satiety, nausea, and dyspnea. These symptoms can be captured in the disease-specific Polycystic Liver Disease Questionnaire (PLD-Q), a validated instrument. The treatment of symptomatic liver cysts is aimed to improve symptoms and quality of life by reducing cyst volume. There are two procedures available to treat symptomatic liver cysts: percutaneous aspiration sclerotherapy and laparoscopic fenestration. In aspiration sclerotherapy, fluid is evacuated from the liver cyst and subsequently the cyst lining is exposed to a sclerosing agent for a limited period of time. Sclerotherapy causes temporary recurrence of cyst fluid after drainage, but subsequently results in a steady decrease of cyst volume in the majority of patients. In laparoscopic fenestration the liver is exposed through laparoscopic surgery. In this procedure the cyst is punctured and drained followed by resection of extra-hepatic cyst wall. The safety and efficacy of aspiration sclerotherapy and laparoscopic fenestration have been explored in two recent systematic reviews. No evident conclusion could be drawn because of the retrospective study design in the vast majority of the studies and the heterogeneity among these. A randomized controlled trial is warranted to identify the possible differences in safety and efficacy in aspiration sclerotherapy and laparoscopic fenestration. Hypothesis: The investigators expect patients treated with laparoscopic fenestration to have better clinical outcome; i.e. a lower PLD-Q score, compared to aspiration sclerotherapy, when measured 4 weeks after the procedure. The investigators expect this difference to become smaller over time (after 6 and 12 months), with loss of statistical significance. Objective: The main objective is to compare laparoscopic fenestration and aspiration sclerotherapy in patients with large symptomatic hepatic cysts on patient-reported outcomes. This information can be used to assess cost-effectiveness in both treatments. Study design: A prospective, randomized clinical superiority trial in which patients will be randomized 1:1 to one of the treatment arms. Patients will be followed for 1 year. Study population: All patients ≥18 years who are diagnosed with a dominant, simple hepatic cyst (>5 cm in diameter), that are symptomatic (PLD-Q score ≥20) and have an indication for treatment (both aspiration sclerotherapy and laparoscopic fenestration) are suitable for inclusion in this study. Only patients that are eligible for both treatments can be included in this study. In particular, patients with multiple cysts (>20 cysts of >1.5 cm) will be excluded as surgery leads to more complications in these patients. Intervention: Patients will be randomly allocated to either aspiration sclerotherapy or laparoscopic fenestration. Both procedures are performed according to the standard Radboudumc protocols. Aspiration sclerotherapy consists of ultrasound-guided, percutaneous drainage of the cyst with subsequent sclerosation with ethanol. Laparoscopic fenestration consists of standard abdominal laparoscopy in which the large cyst(s) are drained and deroofed. Main study parameters: The main study parameter is the PLD-Q score at 4 weeks after treatment. Secondary parameters are among others: PLD-Q score at baseline, 6 months and 12 months; liver volume (CT) at baseline and 4 weeks; cyst volume (ultrasound) at baseline, 4 weeks, 6 months and 12 months; complications according to Clavien-Dindo; admission duration, recurrence and re-intervention rates.


Recruitment information / eligibility

Status Recruiting
Enrollment 70
Est. completion date October 1, 2024
Est. primary completion date October 1, 2023
Accepts healthy volunteers No
Gender All
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria: - Age =18 years - Hepatic cyst characteristics: - Large (>5 cm), - Symptomatic (PLD-Q score =20), - Non-parasitic on imaging (US/CT/MRI) - Non-neoplastic on imaging (US/CT/MRI) - Providing informed consent Exclusion Criteria: - Clinical indication of a complicated hepatic cyst (cyst rupture or active cyst infection) - Cyst is not laparoscopically accessible for surgery - Cyst is not percutaneously (ultrasound-guided) accessible for aspiration - More than 20 cysts of >1.5 cm - Age above 75 years - ASA IV - ECOG score >1 - Aspiration sclerotherapy or laparoscopic fenestration of hepatic cysts was performed in the last 6 months. - Severe renal impairment (eGFR < 30 ml/min/1,73 m2) - Coagulopathy (spontaneous INR >2 or platelet count < 80 x 109/l) - Radiologic contrast allergy - Pregnancy - Any current or prior medical condition that may interfere with the conduct of the study or the evaluation of its results in the opinion of the investigator (e.g. inability to fill out questionnaires).

Study Design


Related Conditions & MeSH terms


Intervention

Procedure:
aspiration sclerotherapy versus laparoscopic fenestration
See arm description

Locations

Country Name City State
Netherlands Radboudumc University Medical Center Nijmegen Gelderland

Sponsors (1)

Lead Sponsor Collaborator
Radboud University Medical Center

Country where clinical trial is conducted

Netherlands, 

Outcome

Type Measure Description Time frame Safety issue
Primary PLD-Q 4 weeks Comparison of PLD-Q scores 4 weeks after the procedure, adjusted for baseline PLD-Q score. 4 weeks after the procedure
Secondary PLD-Q score 1, 6 and 12 months after intervention PLD-Q score at 1, 6 and 12 months after intervention, adjusted for baseline up to 12 months
Secondary PLD-Q invididual symptoms PLD-Q individual symptom scores at 1, 6 and 12 months after intervention, compared to baseline up to 12 months
Secondary SF-36 MCS SF-36 Mental Component Score at 1, 6 and 12 months after intervention, adjusted to baseline up to 12 months
Secondary SF 36 PCS SF-36 Physical Component Score at 1, 6 and 12 months after intervention, adjusted to baseline up to 12 months
Secondary EQ-5D-5L EQ-5D-5L score at 1, 6 and 12 months after intervention, adjusted to baseline up to 12 months
Secondary Liver and cyst volume Liver and cyst volume with CT before and 12 months after the intervention up to 12 months
Secondary Liver and cyst volume at recurrence Liver and cyst volume in cases of recurrence of symptoms up to 12 months
Secondary Cyst volume with US Cyst volume with ultrasound, at baseline and 1, 6 and 12 months after intervention. up to 12 months
Secondary Adverse events Adverse events (according to Clavien-Dindo) up to 12 months
Secondary Technical success Technical success periprocedural
Secondary Hospital stay Hospital stay in days periprocedural
Secondary Re-intervention rates Re-intervention rates during 12 months follow-up. up to 12 months
Secondary Cost-effectiveness iPCQ Cost-effectiveness of both procedures iPCQ 1, 6 and 12 months after intervention, adjusted for baseline up to 12 months
Secondary Cost-effectiveness iMCQ Cost-effectiveness of both procedures iMCQ 1, 6 and 12 months after intervention, adjusted for baseline up to 12 months
See also
  Status Clinical Trial Phase
Recruiting NCT04310319 - Wishing to Decrease Aquaresis in ADPKD Patients Treated With a V2Ra; the Effect of Regulating Protein and Salt N/A
Recruiting NCT03596957 - Subacute Effect of Tolvaptan on Total Kidney Volume in Adult Patients With Autosomal Dominant Polycystic Kidney Disease Phase 4
Terminated NCT04064346 - Efficacy and Safety of Lixivaptan in the Treatment of Autosomal Dominant Polycystic Kidney Disease Phase 3
Completed NCT03203642 - Study of the Efficacy and Safety of Tesevatinib in Subjects With ADPKD Phase 2
Recruiting NCT04111692 - A Prospective Observational Study of Foam Sclerotherapy .
Recruiting NCT04907799 - Daily Caloric Restriction in ADPKD N/A
Completed NCT05401409 - Effect of Beetroot Juice on Reducing Hypertension in Autosomal Dominant Polycystic Kidney Disease N/A
Terminated NCT03918447 - A Trial of Bardoxolone Methyl in Patients With ADPKD - FALCON Phase 3
Terminated NCT03749447 - An Extended Access Program for Bardoxolone Methyl in Patients With CKD (EAGLE) Phase 3
Recruiting NCT05228574 - Treatment of Vascular Stiffness in ADPKD Phase 4
Completed NCT04908462 - To Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Oral AL01211 in Healthy Volunteers Phase 1
Completed NCT03858439 - Dietary Intervention in ADPKD on Tolvaptan N/A
Recruiting NCT06391450 - Study of Empagliflozin in Patients With Autosomal Dominant Polycystic Kidney Disease (EMPA-PKD) Phase 4
Recruiting NCT05478083 - A GnRH Agonist IN Pre-menopausal Women STudy to Treat Severe Polycystic Liver Disease Phase 2
Completed NCT03102632 - A Clinical Trial of Water Therapy for Autosomal Dominant Polycystic Kidney Disease N/A
Recruiting NCT05996731 - Developing a Pipeline to Employ RNA-Seq as a Complementary Diagnostic Tool in Rare Diseases N/A
Recruiting NCT06193616 - Outcome of ADPKD With Octreotide LAR
Completed NCT05646420 - Thyroid Hormones in ADPKD N/A
Completed NCT03366337 - A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases - PHOENIX Phase 2
Active, not recruiting NCT03273413 - Statin Therapy in Patients With Early Stage ADPKD Phase 4